Merck: What the Print Has to Prove Today

Where our screen stands going in

The two standards split: it clears the faith-based (AAOIFI) screen but not our broader anchor screen. We default to protection and do not call it compliant on a divergence.

What the Street expects

Consensus looks for earnings of about $2.09 a share on revenue near $17.3B. Over the next twelve months analysts pencil in $9.32 of earnings per share against $1.26 over the last twelve, growth of about 640%. The median analyst target is $163 (range $105 to $186), 16% above the $140.93 share price, across 25 analysts.

How it has traded on past prints

Across the last 25 reports, the shares moved an average of -0.2% in the five sessions after the print and +7.0% over twenty. The post-earnings drift has been consistent: the first move has tended to keep going.

What options are pricing

Implied volatility near 59% prices a one-week move of roughly ±8.2% (about $129.34 to $152.52). Positioning: the heaviest put open interest sits at $135 and the heaviest call open interest at $160; those strikes tend to act as magnets or walls in the days after.

Levels that matter

At $140.93 the shares sit 10% below the 52-week high of $156.92 and 72% above the low of $82.01 (79% of the way up the range). The 50-day average is $146.64, above the price. The 200-day average is $122.48, below the price.

Valuation going in

The shares trade about 23% below our fair-value estimate: a modest cushion. Our fair-value estimate is $184.01 against the current share price of $140.93. The shares trade at 115.2 times trailing earnings and 15.6 times forward earnings. Revenue is growing about 5% with net margins near 5%.

Our stance

We are not participants, the name fails our principled screen, so we watch it as a sentiment gauge, not a holding.

What the flow says going in

Underlying money flow is neutral (21-day Chaikin Money Flow -0.02, five-day price change -0.5%, as of 2026-10-23, desk flow model): no strong accumulation or distribution signature.